The New Delhi Doctrine: How India’s Supreme Court Is About to Redefine Global Discovery 

The New Delhi Doctrine: How India’s Supreme Court Is About to Redefine Global Discovery 

For years, cross-border discovery followed a predictable rhythm. If you needed evidence from a foreign entity, you invoked the Hague Convention, drafted a Letter Rogatory, and—provided your requests were specific enough—a local court would appoint a commissioner to collect the documents. It was procedural, bureaucratic, and, for the most part, reliable. 

That rhythm just stopped. 

On November 25, 2025, the Madras High Court issued a ruling in Softgel Healthcare Private Limited v. Pfizer Inc. that didn’t just deny a discovery request; it dismantled the legal framework that multinational corporations have relied upon for decades to access evidence from India’s $50 billion pharmaceutical supply chain. The court didn’t find a typo in the paperwork. It went article by article through the Hague Evidence Convention and found four independent reasons to shut the door. 

Now, the Supreme Court of India has taken up the case, directed the Union of India to join as a party, and signaled its intent to “settle the law.” For e-discovery professionals, IP litigators, and anyone managing cross-border disputes involving Indian entities, this is no longer a niche concern. It is a fundamental shift in the balance of power between U.S. litigation demands and Indian judicial sovereignty. 

The Split Verdict That Exposed a Fractured System 

To understand why this ruling is causing such a stir, you have to look at the split-screen moment that preceded it. Pfizer, seeking evidence for a Hatch-Waxman patent dispute in the District of Delaware, filed parallel Letters Rogatory in two different Indian states regarding two different suppliers. 

In Telangana, the High Court handled the request the way most Western practitioners expected. They appointed a Local Commissioner, established a confidentiality club, and allowed the process to move forward. It was the standard playbook that had worked in Bombay, Delhi, and Telangana for over a decade. 

But in Chennai, the Madras High Court took a wrecking ball to that playbook. 

What makes the Softgel ruling so dangerous for parties seeking discovery is not that the court said “no,” but why it said no. The Division Bench articulated a set of principles that, if adopted by the Supreme Court, will effectively redraw the map of international evidence gathering. 

1. The Specificity Trap (Article 3)

The first strike came under Article 3 of the Hague Convention. The court looked at Pfizer’s request for “all documents and electronically stored information” relating to manufacturing and testing and deemed it a fishing expedition. For anyone who has ever drafted a Rule 34 request in U.S. litigation, that language is standard. But the Madras court made it clear: what is acceptable in Delaware is not acceptable in Chennai. Moving forward, requests must be hyper-specific—naming custodians, exact manufacturing sites, and specific test protocols. Broad categories are dead on arrival. 

2. Non-Party Protections (Article 11)

The second strike addressed the status of the evidence holder. Softgel was not a party to the U.S. litigation; it was a witness. The court emphasized that Indian law affords significant protections to non-party witnesses—protections that the court was unwilling to override simply to accommodate a foreign patent dispute. This creates a massive loophole. If the critical evidence resides with a third-party contract manufacturer rather than the named defendant, the Hague route may now be a dead end. 

3. The Sovereignty Clause (Article 12(b))

This is the game-changer. The court noted that Pfizer’s Indian patent application for the drug in question had been refused by the Indian Patent Office. The bench reasoned: why should an Indian court compel an Indian company to hand over proprietary manufacturing data to enforce a patent that India itself declined to grant? 

This is unprecedented. By linking the execution of a foreign discovery request to the status of a domestic patent application, the court has introduced a geopolitical variable into what was previously a procedural exercise. For innovators with weak or contested patent portfolios in India, this ruling effectively blocks their ability to gather evidence from Indian supply chains to enforce the same patents in the U.S. 

4. The Anti-Discovery Bar (Article 23)

Finally, the court invoked Article 23, relying on India’s 2007 declaration that it does not execute requests for pre-trial discovery. While this declaration has existed for years, no appellate court had previously applied it with such force in a pharmaceutical case. The court essentially held that the U.S. model of broad pre-trial discovery is fundamentally incompatible with India’s civil procedure regime. 

The Supreme Court Intervention: Policy Over Procedure 

When Pfizer appealed, the legal community expected the Supreme Court to offer a technical clarification. Instead, they escalated the stakes. 

On January 29, 2026, a bench led by Chief Justice Surya Kant issued notice to Softgel. But the real signal came when the court ordered the Union of India to be made a party. This is not standard practice. It indicates that the Supreme Court views this not as a commercial squabble between a U.S. pharma giant and a local manufacturer, but as a matter of national policy. 

The bench raised a question that cuts to the heart of international comity: Reciprocity. Would American courts show the same cooperative spirit if an Indian company needed evidence from the United States? In an era of increasing judicial nationalism, this question resonates deeply. 

Notably, the court refused to grant a stay. With Pfizer’s Delaware trial looming on April 27, 2026, the lack of interim relief underscores a harsh reality: the urgency of the U.S. court schedule carries zero weight in the Indian judicial hierarchy. 

Why This Changes the Supply Chain Calculus 

India is not just a player in the generic drug market; it is the market. With over 1,500 API plants, dozens of FDA-approved facilities, and a sprawling network of contract testing labs, the country is the manufacturing backbone for generics worldwide. 

In any Hatch-Waxman case where the generic product originates in India, the critical ESI—batch records, bioequivalence studies, stability protocols—resides there. For years, the strategy was straightforward: if the ANDA filer wasn’t cooperative, you went through the Hague Convention. 

If the Supreme Court upholds the Madras reasoning, that route becomes a trap. 

It forces a fundamental shift in litigation strategy. Practitioners can no longer treat the Hague Convention as a safety net. Instead, we must look to alternative architectures for obtaining evidence. 

1. Exhaust U.S.-Based Discovery First

If the ANDA filer has a U.S. subsidiary or a domestic presence, Rule 34 becomes the primary weapon. If the parent and subsidiary share quality management systems or databases, U.S. courts are generally willing to compel production from the domestic entity, irrespective of what is happening in India. This must now be treated as the main event, not a fallback. 

2. The Art of Voluntary Collection

The Softgel ruling creates a perverse incentive to bypass the courts entirely. Where evidence sits with an independent third party—a contract research organization or a testing lab—it may be possible to negotiate a consensual collection using a neutral forensic intermediary. This takes the Indian courts out of the equation. It relies on the third party’s willingness to cooperate, but in an industry where reputation and relationships matter, this route is often faster and more reliable than litigation. 

3. Leverage the 28 U.S.C. § 1782 Loophole

If an Indian entity has a U.S. affiliate, a U.S.-based agent, or filed a Drug Master File through a U.S. representative, that touchpoint may support an application for judicially compelled discovery on American soil under 28 U.S.C. § 1782. This statute allows U.S. district courts to compel discovery for use in foreign proceedings. While it requires a jurisdictional hook, it offers a way to avoid the Indian judiciary altogether. 

The Silence from the West 

Perhaps the most telling aspect of this development is the lack of commentary from major U.S. and international IP firms. A ruling that fundamentally alters the evidentiary landscape for the world’s largest generic drug supplier has generated almost no analysis in Western legal publications. The gap between the ruling’s importance and its visibility is a liability. 

If the Supreme Court formalizes restrictive guidelines—mandating reciprocity, cementing the link between Indian patent validity and discovery cooperation, or affirming the non-party protections—the effects will radiate far beyond the pharmaceutical sector. Any cross-border matter involving Indian entities, from antitrust to trade secret theft, will face a higher evidentiary wall. 

Looking Ahead: The USTR and the Final Word 

The next few months will be pivotal. The Delaware trial is set for late April, and while that case will proceed with or without the Indian evidence, the strategic lessons are already clear. 

We are also watching the USTR’s 2026 Special 301 Report, expected around the same time. If the Supreme Court’s final ruling is as restrictive as the Madras decision, it will give the U.S. government a powerful new data point in its ongoing scrutiny of India’s IP enforcement landscape. India has sat on the Priority Watch List for years. A judicial barrier to evidence collection could sharpen that scrutiny to a knife’s edge. 

For now, the only certainty is uncertainty. But one thing is clear: the old playbook is gone. If you are litigating against a generic entity whose supply chain runs through Chennai, Hyderabad, or Ahmedabad, waiting for the Hague Convention to save you is no longer a viable strategy. The map has been redrawn, and the courts are no longer following the old lines.